TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyManagement of solitary and multiple brain metastases from breast cancerUnsanctifying the sanctuary: challenges and opportunities with brain metastases.The role of BRCA status on prognosis in patients with triple-negative breast cancer.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.Breast cancer brain metastasis: molecular mechanisms and directions for treatment
P2860
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
TBCRC 018: phase II study of i ...... reast cancer brain metastases.
@ast
TBCRC 018: phase II study of i ...... reast cancer brain metastases.
@en
type
label
TBCRC 018: phase II study of i ...... reast cancer brain metastases.
@ast
TBCRC 018: phase II study of i ...... reast cancer brain metastases.
@en
prefLabel
TBCRC 018: phase II study of i ...... reast cancer brain metastases.
@ast
TBCRC 018: phase II study of i ...... reast cancer brain metastases.
@en
P2093
P2860
P50
P1476
TBCRC 018: phase II study of i ...... breast cancer brain metastases
@en
P2093
Allison M Deal
Amal Melhem-Bertrandt
Amy Peterman
Anna M Storniolo
Carey Anders
Catherine Van Poznak
Eric P Winer
Joel Parker
John T Carpenter
Jonathan Berg
P2860
P2888
P304
P356
10.1007/S10549-014-3039-Y
P407
P577
2014-07-08T00:00:00Z
P5875
P6179
1034967860